OSP News

Inhaler Price Cap for Boehringer Ingelheim Products

Posted: 05/30/2024

In an effort to make their inhalers more affordable, Boehringer Ingelheim is capping out-of-pocket costs at $35 per month for eligible patients. Government restrictions exclude people enrolled in federal government insurance programs from co-pay support.

Starting June 1, 2024, eligible patients will pay no more than $35 a month at retail pharmacies for the following inhalers:

  • Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol
  • Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray
  • Spiriva® HandiHaler® (tiotropium bromide inhalation powder)
  • Spiriva® Respimat® 1.25 mcg (tiotropium bromide) Inhalation Spray
  • Spiriva® Respimat® 2.5 mcg (tiotropium bromide) Inhalation Spray
  • Stiolto® Respimat® (tiotropium bromide and olodaterol) Inhalation Spray
  • Striverdi® Respimat® (olodaterol) Inhalation Spray

Click here for more information.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.


OSP Technical Support